SCHEMBL12876283

SCHEMBL12876283

C#Cc1cc(C)cc(-c2csc(Cn3cc(C(=O)OCC)cn3)n2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.38
MAPK1 P28482 1/20 0.37
L3MBTL1 Q9Y468 5/20 0.36
KDM4E B2RXH2 5/20 0.36
HPGD P15428 4/20 0.36
GAA P10253 4/20 0.36
AKT1 P31749 1/20 0.36
CNKSR1 Q969H4 1/20 0.36
MAPT P10636 7/20 0.35
TP53 P04637 1/20 0.35
ALDH1A1 P00352 6/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
PKM P14618 1/20 0.34
APEX1 P27695 1/20 0.34
RECQL P46063 1/20 0.34
RAB9A P51151 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875915 0.91 MAPK1 (0.44) GRM2MAPK1L3MBTL1KDM4EHPGD
SCHEMBL1198487 0.89 KDM4E (0.39) GRM2MAPK1L3MBTL1KDM4EHPGD
SCHEMBL12876280 0.89 GRM2 (0.36) GRM2MAPK1L3MBTL1KDM4EHPGD
SCHEMBL12876118 0.87 GRM2 (0.40) GRM2MAPK1L3MBTL1KDM4EHPGD
SCHEMBL12876290 0.86 MAPK1 (0.38) GRM2MAPK1L3MBTL1KDM4EHPGD
SCHEMBL12875909 0.86 GRM2 (0.39) GRM2MAPK1L3MBTL1KDM4EHPGD
SCHEMBL12875801 0.86 GRM2 (0.45) GRM2MAPK1L3MBTL1KDM4EHPGD
SCHEMBL12875888 0.86 GRM2 (0.39) GRM2MAPK1L3MBTL1KDM4EHPGD
SCHEMBL12875967 0.85 GRM2 (0.42) GRM2MAPK1L3MBTL1KDM4EHPGD
SCHEMBL12876016 0.85 MEN1 (0.39) GRM2MAPK1L3MBTL1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A GRM2 1900/4885MAPK1 255/4885L3MBTL1 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.